dorsaVi Competitors

dorsaVi (ASX:DVL) and (BUX) (CNSX:BUX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares dorsaVi and (BUX)'s net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for dorsaVi and (BUX), as provided by MarketBeat.

Valuation and Earnings

This table compares dorsaVi and (BUX)'s top-line revenue, earnings per share (EPS) and valuation.

(BUX) has lower revenue, but higher earnings than dorsaVi.

Summary

dorsaVi beats (BUX) on 1 of the 1 factors compared between the two stocks.

dorsaVi (ASX:DVL) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for dorsaVi and 12144, as reported by MarketBeat.com.

Profitability

This table compares dorsaVi and 12144's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares dorsaVi and 12144's revenue, earnings per share (EPS) and valuation.

12144 has lower revenue, but higher earnings than dorsaVi.

Summary

dorsaVi beats 12144 on 1 of the 1 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and dorsaVi (ASX:DVL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Earnings & Valuation

This table compares BARD1 Life Sciences and dorsaVi's revenue, earnings per share and valuation.

dorsaVi has higher revenue and earnings than BARD1 Life Sciences.

Analyst Ratings

This is a summary of recent recommendations for BARD1 Life Sciences and dorsaVi, as provided by MarketBeat.

Profitability

This table compares BARD1 Life Sciences and dorsaVi's net margins, return on equity and return on assets.

Summary

dorsaVi beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and dorsaVi (ASX:DVL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Earnings & Valuation

This table compares Charles River Laboratories International and dorsaVi's revenue, earnings per share and valuation.

Charles River Laboratories International has higher earnings, but lower revenue than dorsaVi.

Profitability

This table compares Charles River Laboratories International and dorsaVi's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations for Charles River Laboratories International and dorsaVi, as provided by MarketBeat.

Summary

dorsaVi beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Cryosite (ASX:CTE) and dorsaVi (ASX:DVL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Cryosite and dorsaVi's top-line revenue, earnings per share and valuation.

Cryosite has higher revenue and earnings than dorsaVi.

Profitability

This table compares Cryosite and dorsaVi's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Cryosite and dorsaVi, as provided by MarketBeat.com.

Summary

Cryosite beats dorsaVi on 3 of the 3 factors compared between the two stocks.

dorsaVi (ASX:DVL) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for dorsaVi and Epigenomics, as provided by MarketBeat.

Earnings & Valuation

This table compares dorsaVi and Epigenomics' top-line revenue, earnings per share (EPS) and valuation.

Epigenomics has lower revenue, but higher earnings than dorsaVi.

Profitability

This table compares dorsaVi and Epigenomics' net margins, return on equity and return on assets.

Summary

dorsaVi beats Epigenomics on 1 of the 1 factors compared between the two stocks.